XSHE
000078
Market cap721mUSD
Jul 10, Last price
1.89CNY
1D
1.61%
1Q
-49.87%
Jan 2017
-70.00%
Name
Shenzhen Neptunus Bioengineering Co. Ltd
Chart & Performance
P/E
—
P/S
0.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-8.27%
Revenues
26.67b
-12.04%
Net income
-563m
L-52.82%
CFO
104m
+164.02%
Dividend
Jul 16, 20190.02 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shenzhen Neptunus Bioengineering Co., Ltd. is a pharmaceutical enterprise primarily active in China, focusing on the research, development, production, and sale of various medicinal products. Its offerings span therapeutic categories such as anti-cancer treatments, cardiovascular and cerebrovascular medications, and pharmaceuticals derived from marine sources. Founded in 1989, the company is headquartered in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑00 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||